Quantumzyme Clears OTC Markets Caveat Emptor Designation, Enhancing Investor Confidence
Quantumzyme Corp., a biotechnology firm specializing in computational enzyme engineering, has announced the removal of the ‘Caveat Emptor’ designation by OTC Markets Group. This development signifies the company’s transition to a Current Information issuer with a Verified Profile, showcasing its adherence to the OTCID disclosure framework. The removal comes after Quantumzyme’s concerted efforts to enhance […]